EEF1A2 and cancer: The anti-STn mAb TKH223 holds great promise as a cancer theranostic tool (e.g. for therapy, diagnosis and monitoring of sTn-positive lesions) and was therefore selected for in-depth analysis to decipher its interaction with STn, and to determine its specificity using both various computational and experimental tools.